Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$68.00

-7.99 (-10.51%)

09:09
11/25/16
11/25
09:09
11/25/16
09:09

Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities

  • 04

    Dec

LLY Eli Lilly
$68.00

-7.99 (-10.51%)

11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
11/25/16
RHCO
11/25/16
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly price target lowered to $101 from $107 at SunTrust
SunTrust analyst John Boris removed solanezumab, which he had viewed as a "high risk/high reward" asset, from his model after the company reported a Phase 3 study showed that the drug failed to slow loss of cognitive ability in patients with mild Alzheimer's disease. Boris cut his price target on Lilly shares to $101 from $107, but recommends taking advantage of weakness in the shares, on which he keeps a Buy rating.
11/25/16
UBSW
11/25/16
NO CHANGE
Target $70
UBSW
Neutral
Eli Lilly price target lowered to $70 from $82 at UBS
UBS analyst Marc Goodman lowered his price target on Eli Lilly to $70 from $82 following the halt of its solanezumab drug trial for Alzheimer's. The analyst removed his sales estimates for solanezumab and said that without its contribution he is less optimistic for top-line growth. Goodman recommends investors stay on the sidelines and reiterated his Neutral rating on Eli Lilly shares.
11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.

TODAY'S FREE FLY STORIES

NOW

ServiceNow

$90.00

-0.24 (-0.27%)

15:20
04/26/17
04/26
15:20
04/26/17
15:20
Options
ServiceNow options imply 10.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 12

    Jun

MS

Morgan Stanley

$44.50

0.225 (0.51%)

15:18
04/26/17
04/26
15:18
04/26/17
15:18
Conference/Events
Morgan Stanley management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 22

    May

TRU

TransUnion

$39.72

0.92 (2.37%)

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Conference/Events
TransUnion management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 09

    May

$NSD

NASDAQ Market Internals

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRB

H&R Block

$24.07

-0.175 (-0.72%)

, INTU

Intuit

$119.08

0.32 (0.27%)

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Hot Stocks
Trump Effect: Tax preparers fall as administration promises simpler code »

Shares of publicly-traded…

HRB

H&R Block

$24.07

-0.175 (-0.72%)

INTU

Intuit

$119.08

0.32 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$40.49

-1.47 (-3.50%)

15:16
04/26/17
04/26
15:16
04/26/17
15:16
Conference/Events
Zions Bancorp management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

$NYE

NYSE Market Internals

15:16
04/26/17
04/26
15:16
04/26/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$40.34

0.4 (1.00%)

15:14
04/26/17
04/26
15:14
04/26/17
15:14
Hot Stocks
AT&T, IBEW reach tentative agreement in Midwest wireline contract negotiations »

AT&T announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 16

    May

  • 17

    May

ALNY

Alnylam

$51.35

1.05 (2.09%)

, IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

15:12
04/26/17
04/26
15:12
04/26/17
15:12
Recommendations
Alnylam, Ionis Pharmaceuticals analyst commentary  »

Alnylam data for…

ALNY

Alnylam

$51.35

1.05 (2.09%)

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 09

    May

  • 12

    May

  • 24

    May

  • 06

    Jun

VIX

Volatility Index S&P 500 Options

$10.47

-0.29 (-2.70%)

15:11
04/26/17
04/26
15:11
04/26/17
15:11
Options
Quiet day in the VIX pit as markets see muted reaction to Trump's tax plan »

Quiet day in the VIX pit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$50.51

1.09 (2.21%)

15:10
04/26/17
04/26
15:10
04/26/17
15:10
Recommendations
Seagate analyst commentary  »

Needham would be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    Jun

FFIV

F5 Networks

$138.19

0.26 (0.19%)

15:05
04/26/17
04/26
15:05
04/26/17
15:05
Options
F5 Networks options imply 9.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

USB

U.S. Bancorp

$52.47

0.34 (0.65%)

15:01
04/26/17
04/26
15:01
04/26/17
15:01
Hot Stocks
U.S. Bank names Kate Quinn chief administrative officer »

U.S. Bank announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 19

    Jul

  • 18

    Oct

  • 17

    Jan

T

AT&T

$40.26

0.32 (0.80%)

15:00
04/26/17
04/26
15:00
04/26/17
15:00
Hot Stocks
AT&T CEO 'applauds' FCC initiative to remove 'regulatory cloud' over internet »

AT&T Chairman &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 16

    May

  • 17

    May

AMZN

Amazon.com

$907.62

0.21 (0.02%)

14:55
04/26/17
04/26
14:55
04/26/17
14:55
Hot Stocks
Amazon debuts 'Echo Look' camera, style assistant »

Amazon debuted its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 16

    May

  • 23

    May

MENB

Mendocino Brewing Company, Inc.

14:52
04/26/17
04/26
14:52
04/26/17
14:52
Hot Stocks
Mendocino Brewing Company gets amendment to current credit facility »

Effective April 25,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$50.95

-0.55 (-1.07%)

14:50
04/26/17
04/26
14:50
04/26/17
14:50
Options
Mellanox options imply 9.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 12

    Jun

TWTR

Twitter

$15.99

1.325 (9.04%)

14:47
04/26/17
04/26
14:47
04/26/17
14:47
Recommendations
Twitter analyst commentary  »

Twitter to be valued like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ILG

ILG

$23.68

0.57 (2.47%)

14:41
04/26/17
04/26
14:41
04/26/17
14:41
Options
Notable interest in ILG in-the-money calls »

Notable interest in ILG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 25

    May

III

Information Services

$3.19

-0.02 (-0.62%)

14:38
04/26/17
04/26
14:38
04/26/17
14:38
Conference/Events
Information Services management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

COF

Capital One

$83.86

-1.725 (-2.02%)

14:38
04/26/17
04/26
14:38
04/26/17
14:38
Downgrade
Capital One rating change  »

Capital One downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 31

    May

  • 06

    Jun

MCRN

Milacron

$19.17

0.37 (1.97%)

14:37
04/26/17
04/26
14:37
04/26/17
14:37
Hot Stocks
Milacron says DME subsidiary to expand Greenville facility »

Milacron Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

  • 16

    May

SAGE

SAGE Therapeutics

$73.37

0.52 (0.71%)

14:36
04/26/17
04/26
14:36
04/26/17
14:36
Options
Sage Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CB

Chubb

$139.25

2.13 (1.55%)

14:32
04/26/17
04/26
14:32
04/26/17
14:32
Recommendations
Chubb analyst commentary  »

Chubb price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 18

    May

STX

Seagate

$50.51

1.09 (2.21%)

14:26
04/26/17
04/26
14:26
04/26/17
14:26
Recommendations
Seagate analyst commentary  »

Seagate EPS growth should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.